AI Stock Memo: ALDX - Aldeyra Therapeutics - RankAlpha

ALDX

Rating buyAI Memo

Aldeyra Therapeutics

As of 2026-02-27/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-27 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

No scheduled catalysts flagged.

Expected move: +429%

Biggest risk

Negative or ambiguous trial data, regulatory delays, or the need for dilutive financing would pressure the shares toward the bear target and keep valuation muted.

Invalidation

Break below $5 or thesis failure.

What would change my mind?

Positive clinical or regulatory outcomes and supportive analyst upgrades would validate upside and could re-rate shares toward the bull target within the 12‑month horizon.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-27

Base target

p=60%

Bull target

$12

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Positive clinical or regulatory outcomes and supportive analyst upgrades would validate upside and could re-rate shares toward the bull target within the 12‑month horizon.
ANCHOR: {"price": 5.51, "timestamp_utc": "2026-02-27T13:31:14+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Notes: Bull target (12.12) reflects an internal 12-month upside guardrail (~120% from the anchor) while the base_target (9.25) equals the reported analyst median; some sources list an analyst high of $13.00 which exceeds the internal cap but sits outside our 12-month constraint.
Probabilities sum to 100.0.

BearKey bullets

Dilutive equity raises if cash runway shortens
Negative clinical trial outcomes
Regulatory or reimbursement delays

WatchKey bullets

ANCHOR: {"price": 5.51, "timestamp_utc": "2026-02-27T13:31:14+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Notes: Bull target (12.12) reflects an internal 12-month upside guardrail (~120% from the anchor) while the base_target (9.25) equals the reported analyst median; some sources list an analyst high of $13.00 which exceeds the internal cap but sits outside our 12-month constraint.

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=60%)

Bull/Bear spread: +593% / +185%

Vs latest close: Bull +593% · Base +429% · Bear +185%

Scenario probabilities

Bull Target: $12 (p=20%)Base Target: $9 (p=60%)Bear Target: $5 (p=20%)

Commentary

Analyst consensus sits materially above the broker_last anchor, implying upside if clinical/regulatory news is positive. Coverage dispersion and binary event risk keep sentiment conditional and prone to episodic volatility.

As of 2026-02-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Positive clinical or regulatory outcomes and supportive analyst upgrades would validate upside and could re-rate shares toward the bull target within the 12‑month horizon.

Bear Case

Negative or ambiguous trial data, regulatory delays, or the need for dilutive financing would pressure the shares toward the bear target and keep valuation muted.

Drivers

Scannable catalysts and supporting factors

Positive clinical or regulatory outcomes and supportive analyst upgrades would validate upside and could re-rate shares toward the bull target within the 12‑month horizon.

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-27Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$9.25

Range (USD)

$4.99 - $13.00

Count

Query: Aldeyra Therapeutics Inc Common (ALDX) analyst consensus price target high low average

Aldeyra Therapeutics (ALDX) Stock Forecast and Price Target 2026
Search result #1
According to the 4 analysts' twelve-month price targets for Aldeyra Therapeutics, the average price target is $9.50. The highest price target for ALDX is $10.00 ...
Extracted: $9.50, $10.00Open source
Aldeyra Therapeutics, Inc.: Target Price Consensus and Analysts ...
Search result #2
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 5 ; Last Close Price. 5.280USD ; Average target price. 9.667USD ; Spread / Average Target. +83.08%.
Extracted: $5.28, $9.67Open source
Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News, Quote & History
Search result #3
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know.
Open source
Aldeyra Therapeutics Inc. Analyst Estimates - ALDX - MarketWatch
Search result #4
Stock Price Targets. High, $13.00. Median, $9.50. Low, $7.00. Average, $9.67. Current Price, $4.9900. Yearly Numbers. Estimates. ALDX will report 2025 earnings ...
Extracted: $13.00, $9.50, $7.00, $9.67, $4.99Open source
ALDX Stock Price | Analyst Target 10.00 & Consensus - eToro
Search result #5
The average price target for Aldeyra Therapeutics Inc is ‎$‎10.00. Sign up to eToro for detailed analyst forecasts and price targets. What are analysts' ...
Open source
ALDEYRA THERAPEUTICS, INC. (ALDX) Stock, Price, News ... - MSN
Search result #6
ALDX is rated "Strong Buy" with a 12-month target price of $9.67, a ‎84.89% upside from the current price of $5.23. See more. Strong SellSellHoldBuyStrong ...
Extracted: $9.67, $5.23Open source

Scenarios

Bull Target (Scenario probability)

$12 / p=20% prob

Base Target (Scenario probability)

$9 / p=60% prob

Bear Target (Scenario probability)

$5 / p=20% prob

Price $2 as of 2026-05-29

Nearest Scenario: Bear (∆ 185%)

Targets vs latest close: Bull +593% · Base +429% · Bear +185%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Risks

Dilutive equity raises if cash runway shortens
Negative clinical trial outcomes
Regulatory or reimbursement delays

Peers

No peer data

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Aldeyra Therapeutics Inc Common (ALDX) analyst consensus price target high low average
Analysis date: 2026-02-27